(NYSEMKT: TOVX) Theriva Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.71%.
Theriva Biologics's earnings in 2026 is -$22,969,000.On average, 4 Wall Street analysts forecast TOVX's earnings for 2026 to be -$9,830,209, with the lowest TOVX earnings forecast at -$9,894,459, and the highest TOVX earnings forecast at -$9,637,460. On average, 4 Wall Street analysts forecast TOVX's earnings for 2027 to be -$9,830,209, with the lowest TOVX earnings forecast at -$9,894,459, and the highest TOVX earnings forecast at -$9,637,460.
In 2028, TOVX is forecast to generate -$11,702,630 in earnings, with the lowest earnings forecast at -$13,492,444 and the highest earnings forecast at -$9,637,460.